靶向组织蛋白酶G信号肽的T细胞受体模拟CAR T细胞
研究开发了靶向HLA-A2限制性组织蛋白酶G来源信号肽CG1的T细胞受体模拟CAR T细胞(CG1/A2-CAR T),在体外和体内均显示对HLA-A2阳性急性髓系白血病(AML)和慢性髓系白血病(CML)的有效杀伤,且不影响正常骨髓造血,验证了信号肽作为免疫治疗靶点的可行性。
要点
- CG1/A2 TCR模拟抗体对CG1/A2单体和表达CG1/A2的白血病细胞具有高亲和力。
- CG1/A2-CAR T细胞在体外和体内均能有效杀伤HLA-A2阳性AML和CML细胞。
- CG1/A2-CAR T细胞不影响正常骨髓造血。
核心结论
- 结果验证了信号肽作为免疫治疗靶点的可行性,并为CG1/A2-CAR T细胞在AML和CML中的持续临床开发提供了基础。
研究设计与样本
- 本研究为临床前研究,报告了靶向CG1/A2的嵌合抗原受体T细胞(CG1/A2-CAR T)的构建、临床前疗效和安全性数据,该CAR T细胞利用CG1/A2 TCR模拟抗体构建体。
主要发现
- CG1/A2 TCR模拟抗体对CG1/A2单体和表达CG1/A2的白血病(包括HLA-A2阳性AML和CML)具有高亲和力。
- CG1/A2-CAR T细胞在体外和体内均能有效杀伤HLA-A2阳性AML和CML细胞。
- CG1/A2-CAR T细胞不影响正常骨髓造血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There has been a been a paucity of immunotherapy targets in myeloid malignancies. We identified the HLA-A2 (A2)-restricted, cathepsin G (CG)-derived signal peptide, CG1, as a promising immunotherapeutic target. CG1 is presented by HLA-A2 in acute (AML) and chronic (CML) myeloid leukemia. We previously developed a T cell receptor-mimic antibody (TCR-m) that targets CG1/A2, engineered it into a bispecific T cell engager antibody, and demonstrated its safety and efficacy in AML and CML. In this study, we provide data for the engineering, preclinical efficacy, and safety of CG1/A2-targeting chimeric antigen receptor (CAR) T cells (CG1/A2-CAR T), which utilize the CG1/A2 TCR-m constructs. We show that the CG1/A2 TCR-m has high affinity for CG1/A2 monomers and CG1/A2-expressing leukemia, including HLA-A2+ AML and CML. We demonstrate potent CG1/A2 CAR T killing of HLA-A2+ AML and CML both in vitro and in vivo. Importantly, we found that CG1/A2-CAR T cells did not affect normal bone marrow hematopoiesis. These results validate signal peptides as immunotherapeutic targets and provide a foundation for the continued clinical development of CG1/A2-CAR T cells in AML and CML.
引用
- Yan J, Shi C, Yang G, et al. T cell receptor mimic CAR T cells targeting cathepsin G signal peptide. Leukemia. 2025. PMID: 40437170. doi:10.1038/s41375-025-02652-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。